The American journal of medicine · 2026
Metabolic Dysfunction-Associated Steatotic Liver Disease and Outcomes in Atrial Fibrillation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Danpanichkul Pojsakorn, Pang Yanfang, Duangsonk Kwanjit, Sivakumar Nithila, Tothanarungroj Primrose, Anouti Ahmad, Souza Matheus, Mousa Omar Y, Cotter Thomas G, Kim Donghee, Liangpunsakul Suthat, Krittanawong Chayakrit, Noureddin Mazen
Аннотация
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease is associated with incident atrial fibrillation, but its prognostic significance in established atrial fibrillation is unclear. We evaluated its association with clinical outcomes.
METHODS: We conducted a retrospective cohort study using the TriNetX Research Network. Adults with atrial fibrillation, with or without metabolic dysfunction-associated steatotic liver disease, underwent 1:1 propensity-score matching. Outcomes were assessed for 3 years using Kaplan-Meier and Cox models.
RESULTS: The matched cohort included 19,154 patients (9,577 per group). All-cause mortality was similar between groups (HR 0.94, 95% CI 0.85-1.03). Metabolic dysfunction-associated steatotic liver disease was associated with higher risks of major adverse cardiovascular events (HR 1.14, 95% CI 1.09-1.18), heart failure (HR 1.12, 95% CI 1.07-1.18), heart failure with preserved ejection fraction (HR 1.18, 95% CI 1.11-1.25), heart failure with reduced ejection fraction (HR 1.09, 95% CI 1.02-1.17), myocardial infarction (HR 1.16, 95% CI 1.05-1.27), and chronic kidney disease stage 3 or greater (HR 1.12, 95% CI 1.06-1.18). Ischemic stroke risk was similar (HR 1.03, 95% CI 0.94-1.14).
CONCLUSIONS: In established atrial fibrillation, concomitant metabolic dysfunction-associated steatotic liver disease was associated with modestly higher cardiovascular and renal morbidity but not mortality or stroke. These observational findings identify a risk marker and do not establish causality.
METHODS: We conducted a retrospective cohort study using the TriNetX Research Network. Adults with atrial fibrillation, with or without metabolic dysfunction-associated steatotic liver disease, underwent 1:1 propensity-score matching. Outcomes were assessed for 3 years using Kaplan-Meier and Cox models.
RESULTS: The matched cohort included 19,154 patients (9,577 per group). All-cause mortality was similar between groups (HR 0.94, 95% CI 0.85-1.03). Metabolic dysfunction-associated steatotic liver disease was associated with higher risks of major adverse cardiovascular events (HR 1.14, 95% CI 1.09-1.18), heart failure (HR 1.12, 95% CI 1.07-1.18), heart failure with preserved ejection fraction (HR 1.18, 95% CI 1.11-1.25), heart failure with reduced ejection fraction (HR 1.09, 95% CI 1.02-1.17), myocardial infarction (HR 1.16, 95% CI 1.05-1.27), and chronic kidney disease stage 3 or greater (HR 1.12, 95% CI 1.06-1.18). Ischemic stroke risk was similar (HR 1.03, 95% CI 0.94-1.14).
CONCLUSIONS: In established atrial fibrillation, concomitant metabolic dysfunction-associated steatotic liver disease was associated with modestly higher cardiovascular and renal morbidity but not mortality or stroke. These observational findings identify a risk marker and do not establish causality.